このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Patient Reported Recovery of Muscle Strength After Surgery for Cervical Radiculopathy, Impact of Duration and Severity on Recovery.

2026年9月13日 更新者:Tore Solberg、University Hospital of North Norway

Patient Reported Recovery of Muscle Strength After Surgery for Cervical Radiculopathy, Impact of Duration and Severity on Recovery. A Population Based Study by NOrspine

DCR surgery is generally recommended for patients with severe or progressive limb paresis. The incidence of motor weakness reported to be up to 70%, with a varying recovery rate up to 90%, and the prospects of recovery is most likely dependent on paresis severity and duration. Operative treatment could facilitate earlier recovery, but the evidence is weak and based on smaller and heterogeneous DCM/DCR populations. There is also a lack of knowledge concerning timing of surgery, i.e. the influence of paresis duration, surgical delay and preoperative paresis. It is also unclear if there is an association between the underlying DCR pathology (disc herniation, spondylosis or both) and prognosis. The aim of this sub-study is to assess the frequency and severity of limb preoperative paresis in patients operated for DCR, and to improve prognostication of recovery and timing of surgery. To the best of our knowledge, these issues have not been properly investigated previously.

New knowledge in this field is highly sought by clinicians and can Inform patients, and physicians in shared decision making, i.e. helping them to choose more wisely between different treatment strategies. New insight in this field would be also be useful in clinical guideline development, for reducing surgical practice variation, for modifying outcome expectations, improve patient selection (clinical guideline development) and clinical outcomes of DCR surgery.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

The most common cause of cervical operation is Degenerative cervical radiculopathy (DCR), i.e. a neural impingement by disc herniation or spondylotic changes. While pain is often the most prevalent indication of surgery, motor weakness is frequently reported and is associated with less favourable outcome.

Preoperative motor weakness is reported up to 70%. Some studies suggest that both the severity and duration of preoperative motor weakness are associated with persistent postoperative weakness, implying that delayed intervention may reduce the likelihood of full neurological recovery.

Moreover, current evidence does not establish whether surgery is preferable to conservative treatment in patients with motor weakness. The optimal timing of surgery and the grades of weakness most likely to benefit also remain unclear. A systematic review was unable to draw firm conclusions because studies varied substantially in strength assessment methods, outcome definitions, and follow-up duration.

Thomé et al. reported that, in lumbar radiculopathy, the association between early surgery and motor recovery was dependent on both baseline muscle grade and symptom duration.12 However, these findings may not be generalisable to cervical radiculopathy given key anatomical and pathological differences.

This study aims to evaluate the association between the preoperative duration and baseline severity (muscle strength grade) of motor weakness and complete strength recovery at 12 months after surgery for DCR. As a secondary, exploratory aim, we will assess whether there is a severity grade and/or duration window in which the probability of complete recovery is highest.

Primary Objective Evaluate the association of (1) patient-reported duration of weakness prior to surgery (timing proxy) and (2) baseline objective motor deficit severity (MRC grade) with patient-reported complete strength recovery (Yes/No) at 12 months following single-level surgery for cervical radiculopathy.

Exploratory objectives

  • Identify candidate cut points for timing and/or baseline MRC using tree-based recursive partitioning to predict 12-month complete recovery (cervical-specific threshold discovery).
  • Evaluate predictive discrimination using ROC/AUC for timing, MRC, and combined models (with internal validation if feasible).

Secondary Objectives

  • Assess effect modification (Timing × MRC interaction) for the primary endpoint.
  • Evaluate associations of timing and baseline MRC with NDI and NRS outcomes (arm pain, neck pain, headache) at 12 months (and at 3 months if available). -Evaluate postoperative strength trajectory using a binary outcome measure complete recovery (yes/no) at 3 and 12 months with random effects (Thomé-analogue trajectory analysis under registry constraints).
  • Perform etiology-stratified subgroup analyses (disc herniation vs spondylotic foraminal stenosis) to assess heterogeneity of associations.

Hypothesis Our null hypothesis is that the prognosis of recovery for DCR patients with paresis is independent of paresis severity, duration and underlying pathology. Our alternative hypothesis is that the recovery rate of paresis after DCR surgery is less for more severe paresis of longer duration and will vary according to underlying pathology.

Study populations The study will include consecutive patients operated for DCR and registered in NORspine form January 2012 through 2022, approximately 12.000 cases. Patients operated for cervical myelopathy will be excluded. Otherwise patients under the age of 16, those operated for fractures, tumours and primary infections, as well as those unable to give informed consent, are not included in the NORspine.

Data sources The project will use prospectively collected data from The Norwegian registry for spine surgery NORspine as the only data source, The NORspine is a comprehensive national clinical registry, with a capture rate of patients operated for DCR of 80% from in 2021 and a response rate at one year follow up (2022) of 80%. Coverage at the institutional level is 95-100%. A wide range of established and possible prognostic factors are recorded in the NORspine prior to surgery. Patient reported outcome measures (PROMs), are recorded at admission for surgery (baseline) and 3 and 12 months (maximum follow up time) after surgery.

Predictors / Exposure Variables

-Timing proxy: patient-reported weakness duration prior to surgery (registry item; English translation) Baseline question: "Do you have reduced strength (weakness) in the affected shoulder, arm, or hand?" (Yes/No).

If Yes: duration (choose one; optional numeric field where available):

  • Less than 24 hours (optional: number of hours)
  • Less than one week (optional: number of days)
  • 1 week to 3 months (optional: number of weeks)
  • 3 months to 12 months
  • More than 12 months

Operationalization (prespecified):

  • Primary: derive duration in days when numeric detail is available (hours/days/weeks converted to days).
  • Otherwise: treat duration as an ordered categorical predictor using the registry intervals.
  • Sensitivity: apply a prespecified category-to-days mapping (e.g., midpoint assumptions) when numeric detail is missing; assumptions reported explicitly.

Baseline objective motor deficit severity (MRC) Preoperative MRC grade (0-5) recorded by clinician/surgeon for a prespecified key muscle group corresponding to the index level, according to the institution's standard mapping. The cohort is restricted to objective weakness at baseline (MRC < 5).

Planned MRC coding (depending on data)

  • Primary coding: severe 0-2 /moderate 3 / mild 4
  • Secondary coding: severe ≤3 vs non-severe ≥4. Note: Tree-based methods may identify alternative splits; these will be reported as exploratory and will not redefine confirmatory coding.

Covariates / confounding control Potential confounders/covariates will be evaluated a priori based on clinical knowledge and registry availability by directed acyclic graph (DAG). Adjusted models will be specified before analysis and will not rely on automated or purely significance-driven variable selection.

Statistical Analysis Plan

Primary Confirmatory Analysis (Prediction of 12-month complete recovery)

  • Outcome: complete recovery at 12 months (Yes/No).
  • Model: multivariable logistic regression.
  • Key predictors: weakness duration (days with non-linearity assessment; otherwise ordinal categories) and baseline MRC severity (0-3 vs 4; secondary 0-2/3/4 if feasible).
  • Confounding control: covariates will be evaluated and specified a priori; models will not rely on automated or purely significance-driven variable selection.
  • Effect modification: prespecified duration × MRC interaction; etiology interaction and/or stratified reporting.

Secondary Trajectory Analysis (binary longitudinal strength outcome at 3 and 12 months)

  • Outcome: Complete recovery (yes/no) or complete or improved recovery (yes/no) status at 3 and 12 months
  • Model: logistic mixed-effects model with patient random intercept and fixed effect of time (12 vs 3 months), plus baseline predictors and prespecified interactions.

Exploratory Threshold Discovery (Tree-based)

  • Conditional inference tree / recursive partitioning to identify candidate cervical-specific cut points in duration and/or baseline MRC predicting 12-month complete recovery.
  • Internal validation via cross-validation and/or bootstrap where feasible.
  • Tree-based methods are used only for exploratory threshold discovery and will not be used for confounder selection.

Exploratory Discrimination (ROC/AUC)

•ROC/AUC for models using (a) timing alone, (b) MRC alone, and (c) combined predictors, with internal validation if feasible.

Missing Data

  • Describe extent/patterns of missingness in predictors and outcomes.
  • Primary analysis: complete-case for required 12-month outcome; sensitivity analyses as appropriate.
  • Longitudinal models incorporate partially observed 3/12-month outcomes under MAR conditional on observed covariates and earlier outcomes; sensitivity analyses may include inverse probability weighting and/or multiple imputation.

研究の種類

観察的

入学 (実際)

2000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Tromsø、ノルウェー、9010
        • Neurosurgical department, University Hospital of North Norway

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

確率サンプル

調査対象母集団

The study will include consecutive patients operated for DCR and registered in NORspine form January 2012 through 2022, approximately 12.000 cases. Patients operated for cervical myelopathy will be excluded. Otherwise patients under the age of 16, those operated for fractures, tumours and primary infections, as well as those unable to give informed consent, are not included in the NORspine.

説明

Inclusion Criteria:

  • Surgery due to degenerative cervical radiculopathy with a preoperative muscle weakness
  • Posterior and anterior approach (ACDF/artificial disc replacement, posterior foramenotomi)

Exclusion Criteria:

  • Myelopathy as surgical indication
  • Tumor as surgical indication
  • Infection as surgical indication
  • Fracture as surgcial indication
  • Posterior fusion and laminectomy
  • Prior cervical surgery
  • Anterior corpectomy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
patient reported improvement of paresis (complete)
時間枠:12 month

Follow-up strength question (3 and 12 months): "If you had reduced strength (weakness) in your shoulder/arm/hand before the operation-has this changed?"

Response options:

  • Has become completely normal
  • Has improved
  • Unchanged
  • Has worsened

Primary endpoint derivation (12 months):

  • Complete recovery = Yes: "Has become completely normal".
  • Complete recovery = No: all other responses.
12 month

二次結果の測定

結果測定
メジャーの説明
時間枠
Neck disability index (NDI)
時間枠:12 month
Neck disability index (NDI) is a measure of neck pain related disability, containing 10 items (pain, personal care, lifting, reading, headaches, concentration, work, driving, sleeping and recreation), all scored on a 6-point ordinal scale (0-5). The 10 items are summarized and recalculated to a percentage score ranging from 0 to 100 (no to maximum disability). Change from baseline to 12 month follow up will be computed. NDI change will be dichotomized to success yes/no as 35% improvement
12 month
EuroQol-5D (EQ5D)
時間枠:12 month
EuroQoL (EQ-5D-3L) is a generic measurement and preference-weighted measure of health-related quality-of- life based on five dimensions: mobility, self-care, usual activity, pain/discomfort and anxiety/discomfort. For each dimension the patient assesses three possible levels (3L) of problems; "none," "mild to moderate," and "severe." The score ranges from 0.59 to 1, where 1 corresponds to perfect health and 0 to death and negative values worse than death. In the second part, called the EQ-VAS, the patient is asked to indicate overall health on a vertical analogue scale, ranging from 0 to 100 ("worst to "best imaginable health").
12 month
Patient and surgeon reported complications
時間枠:12 month
intra and post operativ complications
12 month
NRS head
時間枠:12 month
Numeric Rating Scale for Headache (NRS-HA) assesses pain severity ranging from 0 to 10 ("no" to "worst conceivable pain"). Change from baseline to 12 month follow up will be computed.
12 month
NRS neck
時間枠:12 month
Numeric Rating Scale for neck (NRS-NE) assesses pain severity ranging from 0 to 10 ("no" to "worst conceivable pain"). Change from baseline to 12 month follow up will be computed.
12 month
NRS head
時間枠:12 month
Numeric Rating Scale for arm (NRS-AR) assesses pain severity ranging from 0 to 10 ("no" to "worst conceivable pain"). Change from baseline to 12 month follow up will be computed.
12 month
Improved or complete recovery
時間枠:12 and 3 month

Follow-up strength question (3 and 12 months): "If you had reduced strength (weakness) in your shoulder/arm/hand before the operation-has this changed?"

Response options:

  • Has become completely normal
  • Has improved
  • Unchanged
  • Has worsened
  • Binary outcome improvement (yes/no) at 3 and 12 months: yes (Has become completely normal and Has improved) and no (Unchanged and Has worsened)
12 and 3 month

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2012年1月1日

一次修了 (実際)

2023年12月31日

研究の完了 (実際)

2023年12月31日

試験登録日

最初に提出

2026年9月13日

QC基準を満たした最初の提出物

2026年9月13日

最初の投稿 (実際)

2026年9月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月17日

QC基準を満たした最後の更新が送信されました

2026年9月13日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 03276-2

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

Do to norwegian privacy and research laws

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。